Ref. 47-2023 Bioinformatician for the Cancer Genomics Lab
The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Bioinformatician for the Cancer Genomics Lab”
Reference: Ref. 47-2023
Application deadline: 30/06/2023
Number of vacancies: 1
We are seeking a bioinformatician to join the Cancer Genomics Lab at VHIO. The scope of the work will be mostly linked to the analysis of genomic data in the context of cancer patients. The successful applicant should be able to work in a team as well as independently and in several projects, be proactive and motivated.
- Bioinformatician with knowledge/ experience in Genomics and Cancer (+2yrs).
- Familiar with raw sequencing data (FASTQ) as well as other common formats (SAM/BAM, BED, etc.), command-line tools (bwa, samtools, bedtools, etc.) and biological databases (cBioportal, COSMIC…).
- Fluency in R and/ or Python.
- Proficiency in English.
- Knowledge of statistical modelling or machine learning will be considered a plus.
- Knowledge in database management systems (such as MySQL, mongoDB or noSQL).
- Experience in Docker and/ or Slurm.
Candidates must submit a curriculum vitae and letter of intent via email: email@example.com, including the reference number.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.